Cencora, Inc.

COR 10-Q · Q3 2025
API behind this page

COR Q3 2025 request

Playground key active
Request URL /api/financials?ticker=COR&year=2025&quarter=3
waiting 0 ms 
Pick an endpoint and run the request.
curl

Income Statement

JSON CSV Excel
Income Statement
Metric Q3 2025 Q3 2024 YoY
Revenue 80,663,532 74,241,353 +8.7%
Show Business Segments breakouts
International Healthcare Solutions · Alliance Healthcare 6,229,964 5,641,912 +10.4%
International Healthcare Solutions · Operating Segments 7,790,438 7,051,876 +10.5%
International Healthcare Solutions · Other Healthcare Solutions 1,560,474 1,409,964 +10.7%
U. S. Healthcare Solutions · Animal Health 1,471,692 1,369,735 +7.4%
U. S. Healthcare Solutions · Human Health 71,404,871 65,821,863 +8.5%
U. S. Healthcare Solutions · Operating Segments 72,876,563 67,191,598 +8.5%
Show Consolidation Items breakouts
Intersegment Elimination -3,469 -2,121 -63.6%
Cost of Revenue 77,756,417 71,830,576 +8.2%
Gross Profit 2,907,115 2,410,777 +20.6%
Selling, General & Administrative 1,672,881 1,383,206 +20.9%
Depreciation Nonproduction 128,128 107,940 +18.7%
Amortization Of Intangible Assets 125,867 164,655 -23.6%
Litigation Settlement Expense 17,974 14,485 +24.1%
Show Consolidation Items breakouts
Material Reconciling Items 17,974 14,485 +24.1%
Business Combination Acquisition Related Costs 52,838 25,758 +105.1%
Show Consolidation Items breakouts
Material Reconciling Items 52,838 25,758 +105.1%
Restructuring Charges 41,773 42,257 -1.1%
Show Consolidation Items breakouts
Material Reconciling Items 41,773 42,257 -1.1%
Operating Income 867,654 672,476 +29.0%
Show Business Segments breakouts
International Healthcare Solutions · Operating Segments 156,222 179,391 -12.9%
U. S. Healthcare Solutions · Operating Segments 901,793 698,305 +29.1%
Show Consolidation Items breakouts
Intersegment Elimination 316 — —
Operating Segments 1,058,331 877,696 +20.6%
Non-Operating Income (Expense) -110,417 12,814 -961.7%
Interest Income Expense Nonoperating Net 81,794 31,328 +161.1%
Income Before Taxes 896,277 628,334 +42.6%
Income Tax Expense (Benefit) 206,528 140,740 +46.7%
Net Income 689,749 487,594 +41.5%
Show Equity Components breakouts
Noncontrolling Interest 2,347 4,131 -43.2%
Retained Earnings 687,402 483,463 +42.2%
Net Income Loss Attributable To Noncontrolling Interest -2,347 -4,131 +43.2%
Net Income 687,402 483,463 +42.2%
EPS (Basic) 3.55 2.44 +45.5%
EPS (Diluted) 3.52 2.42 +45.5%
Wtd Avg Shares (Basic) 193,822 198,260 -2.2%
Wtd Avg Shares (Diluted) 195,230 200,047 -2.4%
Common Stock Dividends Per Share Declared 0.55 0.51 +7.8%
Comprehensive Income 1,045,002 464,582 +124.9%

Balance Sheet

Balance Sheet
Metric Q3 2025 Q3 2024 YoY
Current Assets
Cash & Cash Equivalents 2,231,852 3,306,200 -32.5%
Accounts Receivable 24,561,733 — —
Inventory 20,137,849 18,301,546 +10.0%
Show Consolidated Entities breakouts
Variable Interest Entity Primary Beneficiary 276,422 256,024 +8.0%
Contract With Customer Asset Gross Current 1,431,363 1,143,731 +25.1%
Prepaid Expenses & Other Current Assets 451,364 459,662 -1.8%
Total Current Assets 48,814,161 47,307,262 +3.2%
Non-Current Assets
Property, Plant & Equipment 2,431,376 2,080,879 +16.8%
Show Consolidated Entities breakouts
Variable Interest Entity Primary Beneficiary 60,487 46,221 +30.9%
Goodwill 14,326,057 — —
Show Business Segments breakouts
International Healthcare Solutions 3,309,832 — —
U. S. Healthcare Solutions 11,016,225 — —
Show Reporting Unit breakouts
PharmaLex Acquisition 723.9 — —
Deferred Tax Assets 228,287 229,653 -0.6%
Other Non-Current Assets 4,227,970 3,530,066 +19.8%
Show Consolidated Entities breakouts
Variable Interest Entity Primary Beneficiary 94,518 77,805 +21.5%
Total Assets 73,956,905 66,772,423 +10.8%
Show Consolidated Entities breakouts
Variable Interest Entity Primary Beneficiary 848,034 734,663 +15.4%
Intangible Assets (Q) — — —
Show Finite Lived Intangible Assets By Major Class breakouts
Customer Relationships 3,500,641 3,480,267 +0.6%
Trade names and other 411,413 513,625 -19.9%
Other Assets
Intangible Assets Net Excluding Goodwill 3,929,054 4,010,892 -2.0%
Current Liabilities
Accounts Payable 51,043,874 49,883,049 +2.3%
Accrued Liabilities 2,717,373 2,525,710 +7.6%
Debt Current 196,787 565,108 -65.2%
Total Current Liabilities 53,958,034 52,973,867 +1.9%
Current Portion of Long-Term Debt (Q) — — —
Show Debt Instrument breakouts
Alliance Healthcare debt 66,677 — —
Nonrecourse debt 130,110 — —
Non-Current Liabilities
Long-Term Debt 8,043,699 — —
Accrued Income Taxes Noncurrent 306,297 332,364 -7.8%
Deferred Tax Liabilities 1,614,723 1,607,661 +0.4%
Show Consolidated Entities breakouts
Variable Interest Entity Primary Beneficiary 14,337 24,099 -40.5%
Litigation Reserve Noncurrent 4,284,602 4,697,695 -8.8%
Show Litigation Case breakouts
Opioid Lawsuits and Investigations 4.3 — —
Other Non-Current Liabilities 3,539,659 1,934,423 +83.0%
Show Consolidated Entities breakouts
Variable Interest Entity Primary Beneficiary 70,758 55,532 +27.4%
Long-Term Debt 8,240,486 — —
Show Debt Instrument breakouts
$1,000,000, 2.700% senior notes due 2031 993,558 — —
$500,000, 2.800% senior notes due 2030 497,022 — —
$500,000, 4.250% senior notes due 2045 495,737 — —
$500,000, 4.300% senior notes due 2047 494,021 — —
$500,000, 4.625% senior notes due 2027 497,003 — —
$500,000, 5.125% senior notes due 2034 494,957 — —
$600,000, 4.850% senior notes due 2029 596,401 — —
$700,000, 5.150% senior notes due 2035 694,771 — —
$750,000, 3.450% senior notes due 2027 747,940 — —
Alliance Healthcare debt 66,677 — —
Nonrecourse debt 200,408 — —
Term loan due in 2027 1,298,996 — —
€500,000, 2.875% senior notes due 2028 582,556 — —
€500,000, 3.625% senior notes due 2032 580,439 — —
Show Consolidated Entities breakouts
Variable Interest Entity Primary Beneficiary 70,298 — —
Total Liabilities (Q) — — —
Show Consolidated Entities breakouts
Variable Interest Entity Primary Beneficiary 641,595 546,983 +17.3%
Other Liabilities
Minority Interest 229,698 135,294 +69.8%
Stockholders' Equity
Common Stock 2,973 2,961 +0.4%
Additional Paid In Capital Common Stock 6,172,015 5,989,201 +3.1%
Retained Earnings 6,981,443 5,514,702 +26.6%
Accumulated Other Comprehensive Income -844,238 -1,279,169 +34.0%
Treasury Stock Common Value -10,332,000 -9,302,486 -11.1%
Total Stockholders' Equity 1,980,193 925,209 +114.0%
Stockholders Equity Including Portion Attributable To Noncontrolling Interest 2,209,891 1,060,503 +108.4%
Show Equity Components breakouts
Accumulated Other Comprehensive Income -844,238 -1,279,169 +34.0%
Additional Paid In Capital 6,172,015 5,989,201 +3.1%
Common Stock 2,973 2,961 +0.4%
Noncontrolling Interest 229,698 135,294 +69.8%
Retained Earnings 6,981,443 5,514,702 +26.6%
Treasury Stock Common -10,332,000 -9,302,486 -11.1%
Total Liabilities & Equity 73,956,905 66,772,423 +10.8%

Cash Flow Statement

Cash Flow Statement
Metric YTD Q3 2025 YTD Q3 2024 YoY
Operating Activities
Depreciation 367,582 336,955 +9.1%
Adjustment For Amortization 436,836 502,136 -13.0%
Provision For Doubtful Accounts 45,514 30,216 +50.6%
Deferred Income Taxes 4,475 -106,076 +104.2%
Stock-Based Compensation 122,020 113,410 +7.6%
Inventory L I F O Reserve Period Charge -19,913 -64,441 +69.1%
Show Consolidation Items breakouts
Material Reconciling Items -19,913 -64,441 +69.1%
Inflationary Accounting Impact 42,859 44,664 -4.0%
Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 74,920 — —
Show Business Acquisition breakouts
RCA · Contingent Consideration, Embedded Option Feature 74.9 — —
Gain Loss On Sale Of Business 35,539 — —
Equity Investment Remeasurement Gain Loss -30,559 24,752 -223.5%
Gain Loss On Sale Of Investments -12,838 — —
Other Non-Cash Items -29,954 15,717 -290.6%
Change in Accounts Receivable -977,608 -3,085,563 +68.3%
Change in Inventory -949,881 -835,633 -13.7%
Change in Prepaid & Other Assets 237,814 159,473 +49.1%
Change in Accounts Payable -61,892 4,112,542 -101.5%
Increase Decrease In Other Accounts Payable And Accrued Liabilities -316,650 -87,271 -262.8%
Increase Decrease In Income Taxes Payable And Other Liabilities -127,446 -97,896 -30.2%
Net Cash from Operations 741,703 2,484,306 -70.1%
Investing Activities
Capital Expenditures -418,169 -304,849 -37.2%
Payments To Acquire Businesses Net Of Cash Acquired -4,004,220 -24,487 -16252.4%
Payments To Acquire Equity Method Investments -193,792 -14,981 -1193.6%
Payments To Acquire Notes Receivable -34,814 -50,000 +30.4%
Other Investing Activities -4,358 18,106 -124.1%
Net Cash from Investing -4,655,353 -376,211 -1137.4%
Financing Activities
Proceeds From Issuance Of Debt 4,508,482 688,321 +555.0%
Repayments Of Long Term Debt -763,412 -659,255 -15.8%
Proceeds From Lines Of Credit 86,153,436 56,683,347 +52.0%
Repayments Of Lines Of Credit -86,120,601 -56,744,334 -51.8%
Payments For Repurchase Of Equity -435,471 -986,388 +55.9%
Proceeds From Stock Options Exercised 22,613 31,560 -28.3%
Payments Of Dividends Common Stock -329,569 -315,223 -4.6%
Tax Withholding for Share Compensation -77,674 -60,121 -29.2%
Proceeds From Payments For Other Financing Activities -24,908 -11,641 -114.0%
Net Cash from Financing 2,932,896 -1,373,734 +313.5%
Share Repurchases 435.4 986,388 -100.0%
Other Cash Flow
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations -41,800 -10,854 -285.1%
Net Change in Cash -1,022,554 723,507 -241.3%
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents 2,275,326 3,476,396 -34.5%
Show Consolidated Entities breakouts
Variable Interest Entity Primary Beneficiary 37,831 — —

Values in thousands USD. Source: SEC EDGAR 10-Q filing.

This table is rendered from the same JSON returned by /api/financials.

Get API Key